“In 2017, the Top 5 Vaccines Manufacturers held 76% of the Global Vaccines Market” says new Visiongain report

12 February 2019
Pharma

Visiongain has launched a new pharma report Top 20 Vaccines Manufacturers 2019: Merck & Co., Sanofi, Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Emergent Biosolutions, Other Companies

The world vaccines market is set to grow steadily over the next 10 years. This growth is mainly driven by a global ageing population, as the elderly are more prone to contracting infections due to their pre-existing health conditions and a weak immune system. Demand from the emerging markets further drive growth as their middle class gets wealthier and demand better healthcare systems, furthermore the high birth rates in the emerging markets will feed the paediatric vaccines segment. Moreover, the vaccine industry benefits from strong research and development leading to continuous innovation. Technological advancements will be made in vaccine delivery and administration. As a result, the development of more efficient technology will reduce costs of vaccine production, making the entire manufacturing and supply chain more efficient.

The lead analyst of the report commented "Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development. New target sites, ways of generating an immune response and method of administration are already being investigated and, in some cases, successfully implemented. Further progress is expected to be made in this field as companies look for other ways to gain a competitive edge over their rivals, which could just be another way of administering an existing vaccine. This factor is expected to provide strong growth opportunities to vaccines manufacturers."

Leading companies featured in the report include Astellas Pharma Inc., AstraZeneca, Bavarian, Nordic, CSL Ltd., Emergent Biosolutions, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline PLC, Inovio Pharmaceuticals and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever